NCT05116267View on ClinicalTrials.gov

Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

October 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Atrial Fibrillation
Trial Locations (1)

Unknown

Pfizer Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05116267 - Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium | Biotech Hunter | Biotech Hunter